The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The RANKL/RANK/OPG pathway
Abstract
Understanding of osteoclast formation and activation has advanced considerably since the discovery of the RANKL/RANK/OPG system in the mid 1990s. Osteoblasts and stromal stem cells express receptor activator of NF-jB ligand (RANKL), which binds to its receptor, RANK, on the surface of osteoclasts and their precursors. This regulates the differentiation of precursors into multinucleated osteoclasts and osteoclast activation and survival both normally and in most pathologic conditions associated with increased bone resorption. Osteoprotegerin (OPG) is secreted by osteoblasts and osteogenic stromal stem cells and protects the skeleton from excessive bone resorption by binding to RANKL and preventing it from interacting with RANK. The RANKL/OPG ratio in bone marrow is thus an important determinant of bone mass in normal and disease states. RANKL/RANK signaling also regulates lymph node formation and mammary gland lactational hyperplasia in mice, and OPG protects large arteries of mice from medial calcification. This article reviews the roles of the RANKL/RANK/OPG system in bone and other tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been shown that the receptor activator of nuclear factor-kappa B ligand (RANKL)-RANK-osteoprotegerin (OPG) (RANKL-RANK-OPG) pathway exerts a crucial role in osteoclast differentiation and bone resorption [87,88,89].”
From An Overlooked Bone Metabolic Disorder: Cigarette Smoking-Induced Osteoporosis (2022) · cites this paper as [87]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., & de Crombrugghe, B. (2002) · Cell · doi:10.1016/s0092-8674(01)00622-5 · Cited by 3,608
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878
Genetic regulation of osteoclast development and function
Teitelbaum, S. L., & Ross, F. P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1122 · Cited by 1,720
T-Cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ.
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000) · Nature · doi:10.1038/35046102 · Cited by 1,358
Research works printed but not linked: 2
- American Society for Bone and Mineral Research President’s Committee on Nomenclature: Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President’s Committee on Nomenclature. J Bone Miner Res 2000, 15:2293–2296.
- Yao Z, Matsuo K, Nishimura R, et al.: c-Fos/NFAT1-or 2-mediated osteoclastogenesis requires NF-κB p50/p52 expression [abstract]. J Bone Miner Res 2005, 20(suppl 1):S145.
Cited by
Sorted by citations
Coupling of bone resorption and formation by RANKL reverse signalling
Ikebuchi, Y., Aoki, S., Honma, M., Hayashi, M., Sugamori, Y., Khan, M., Kariya, Y., Kato, G., Tabata, Y., Penninger, J. M., et al. (2018) · Nature · doi:10.1038/s41586-018-0482-7 · Cited by 557
RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling
Tobeiha, M., Moghadasian, M. H., Amin, N., & Jafarnejad, S. (2020) · BioMed Research International · doi:10.1155/2020/6910312 · Cited by 309
Osteoporosis in Inflammatory Bowel Disease
Ali, T., Lam, D. W.-H., Bronze, M. S., & Humphrey, M. B. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.01.022 · Cited by 277
Goldner, W. S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011155 · Cited by 241
Role of osteopontin in bone remodeling and orthodontic tooth movement: a review
Singh, A., Gill, G., Kaur, H., Amhmed, M., & Jakhu, H. (2018) · Progress in Orthodontics · doi:10.1186/s40510-018-0216-2 · Cited by 229
Metadata
- Authors
- Boyce, B. F., & Xing, L.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- Boyce, Brendan F.
- Venue
- Current Osteoporosis Reports
- Published
- 2007-09
- Volume
- 5
- Issue
- 3
- Pages
- 98-104
- ISSN
- 1544-1873 (ISSN-L)
- 1544-2241
- OpenAlex
- W2055590859
- Cited by
- 339
- References
- 48
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 32 · 2023: 29 · 2022: 30 · 2021: 26 · 2020: 31 · 2019: 21 · 2018: 24 · 2017: 25 · 2016: 20 · 2015: 17 · 2014: 4 · 2013: 8 · 2012: 5
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Osteoporosis Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- RANK/RANKL/OPG pathway, osteoclastogenesis, osteoclast activation, bone resorption, osteoblasts, stromal stem cells, RANKL/OPG ratio, bone mass regulation, vascular calcification, NF-κB signaling
- MeSH terms
- Humans, Osteoclasts, Osteoporosis, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
